




SUPPLEMENTARY FIGURES




Supplementary Figure 1. Dynamic expression patterns of five Car-Lncs include DCHS1-AS1 (A, B), LEF1-AS1-201 (C-E), LINC01871 (F-H), THBS1-IT1 (I-K) and WDR11-DT-201 (M-O).




Supplementary Figure 2. The entire analytical process of the study.




Supplementary Figure 3. Comparison of expression levels of 8 CarLncs between tumor and adjacent tissues of KIRC patients.




Supplementary Figure 4. Comparisons of the expression level of 8 CarLncs and clinicopathological variables.




Supplementary Figure 5. Validation of LncAging_score in training (A–E) and validation (F–J) cohort. (A, F) ROC curves to predict the sensitivity and specificity of 1-, 3-, and 5-year survival according to the LncAging_score. (B, G) KM analysis of the OS between the two groups. (C, D, H, I) The ranked dot plot indicates the LncAging_score distribution and scatter plot presenting the patients’ survival status. (E, J) Expression patterns of 5 selected prognostic genes in high- and low-risk groups.




Supplementary Figure 6. The independent prognosis analysis of LncAging_score and clinicopathological variables in KIRC. Univariate (left panel) and multivariate (right panel) analyses showed the prognostic value of the LncAging_score in the entire cohort.




Supplementary Figure 7. Kaplan-Meier analysis of the association between *THBS1-IT1* (ensemble ID: ENSG00000276107) expression and OS. (A) ACC; (B) BLCA; (C) GBM; (D) HNSC; (E) KIRC; (F) LGG; (G) MESO; (H) PAAD; (I) STAD; (J) THCA.




Supplementary Figure 8. Forest plot of association of *THBS1-IT1* with disease-specific survival (DSS) for 33 types of tumors.




Supplementary Figure 9. Kaplan-Meier analysis of the association between *THBS1-IT1* (ensemble ID: ENSG00000276107) expression and DSS. (A) ACC; (B) PAAD; (C) GBM; (D) HNSC; (E) KIRC; (F) LGG.




Supplementary Figure 10. Forest plot of association of *THBS1-IT1* with disease-free interval (DFI) for 33 types of tumors.




Supplementary Figure 11. Kaplan-Meier analysis of the association between *THBS1-IT1* (ensemble ID: ENSG00000276107) expression and DFI in LUAD (A), LUSC (B) and SARC (C).




Supplementary Figure 12. Forest plot of association of *THBS1-IT1* with progression-free interval (PFI) for 33 types of tumors.




Supplementary Figure 13. Kaplan-Meier analysis of the association between *THBS1-IT1* (ensemble ID: ENSG00000276107) expression and PFI. (A) UVM; (B) GBM; (C) HNSC; (D) KIRC; (E) LGG; (F) LUAD; (G) LUSC; (H) PAAD.



Supplementary Figure 14. Correlation between *THBS1-IT1* expression and immune scores in 33 types of tumors.




Supplementary Figure 15. Correlation between *THBS1-IT1* expression and stromal scores in 33 types of tumors.




Supplementary Figure 16. Correlation between TREM2 expression and immune cell infiltration in ESCA, LIHC and LUSC.

Tumor mutation burden



Supplementary Figure 17. Associations between *THBS1-IT1* expression and tumor mutational burden (TMB). The correlation coefficient * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

Microsatellite instability



Supplementary Figure 18. Associations between *THBS1-IT1* expression and microsatellite instability (MSI). The correlation coefficient * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.